Results 81 to 90 of about 11,948 (164)

Selective Janus kinase inhibitors exhibit different effects in murine immune aplastic anemia

HemaSphere, Volume 10, Issue 3, March 2026.
Jibran Durrani, Xingmin Feng, Zhijie Wu, Shouguo Gao, Ash Lee Manley, Liangliang Wu, Joshua Glass, Bhavisha A. Patel, Jichun Chen, Neal S. Young, Emma M. Groarke   +10 more
wiley   +1 more source

Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre

RMD Open
Objective To investigate the treatment efficacy and safety of baricitinib in patients with refractory Takayasu arteritis (TAK).Methods We performed a prospective cohort study in which baricitinib 4 mg daily was prescribed to patients with refractory TAK,
Jing Li, Li Wang, Li Zhang, Xiaofeng Zeng, Xinping Tian, Shangyi Jin, YunJiao Yang, Ziyue Zhou, Chenglong Fang   +8 more
doaj   +1 more source

The Emerging Role of Gut Microbiota in Inflammatory Skin Diseases: A Systematic Review

Experimental Dermatology, Volume 35, Issue 3, March 2026.
ABSTRACT The human gut microbiota is involved in immune regulation, metabolism, and skin homeostasis. In recent years, gut microbiota alterations have been linked with several inflammatory skin disorders, such as atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa (HS).
Andrea Malgesini, Matteo Domenico Marsiglia, Elisa Borghi, Angelo V. Marzano, Gianluca Nazzaro   +4 more
wiley   +1 more source

Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO‐2b/3

International Journal of Dermatology, Volume 65, Issue 3, Page 526-534, March 2026.
ABSTRACT Background Patients with alopecia areata (AA) in ALLEGRO‐2b/3 (NCT03732807) had clinically significant hair regrowth and patient‐reported improvements with ritlecitinib versus placebo, but patient‐reported improvements in AA Patient Priority Outcomes (AAPPO) emotional symptoms (ES) or activity limitations (AL) were not observed during the 24 ...
Ernest H. Law, Bintu Sherif, Arash Mostaghimi, Brett King, Rodney Sinclair, Natasha Mesinkovska, Kent A. Hanson, Dane Korver, Costel Chirila   +8 more
wiley   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 3, Page 415-422, March 2026.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source

Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects

RMD Open
Objective Obesity and age are strongly linked to severe COVID-19 pneumonia where immunomodulatory agents including Janus kinase inhibitors have shown benefits but the efficacy of such therapy in viral pneumonia is not well understood.
Abdulla Watad, Dennis G McGonagle, Howard Amital, Tom Macleod, Or Hen, Paula David, Niv Ben-Shabbat   +6 more
doaj   +1 more source

“Nomen Omen: The Myth of God Janus”

JEADV Clinical Practice, Volume 5, Issue 1, Page 270-271, March 2026.
Alba Guglielmo
wiley   +1 more source

Inflammatory niches as spatial drivers of disease mechanisms and targets for personalized treatment

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 3, Page 423-430, March 2026.
This study provides a comprehensive review of how spatial transcriptomics reveals disease‐specific inflammatory niches across multiple skin disorders, highlighting key immune–stromal, neuro–immune and metabolic interactions that were previously unappreciated in non‐spatial analyses. Abstract Disease states are increasingly recognized as being shaped by
Rundong Jiang, Zhiqin Fang, Lam C. Tsoi, Johann E. Gudjonsson   +3 more
wiley   +1 more source

Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials

JEADV Clinical Practice
Background Alopecia areata (AA) is an autoimmune hair loss disorder associated with high rates of emotional and psychosocial distress. Baricitinib, an oral selective Janus kinase (JAK) 1 and JAK 2 inhibitor, was superior to placebo with respect to hair ...
Bianca M. Piraccini, Manabu Ohyama, Brittany Craiglow, Anthony Bewley, Yuxin Ding, Yun‐Fei Chen, Yves Dutronc, Evangeline Pierce, Frederick Durand, Arash Mostaghimi   +9 more
doaj   +1 more source

Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care

Diseases
COVID-19 infection is caused by the novel severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2). This novel virus has transformed into different resistant variants (e.g., omicron; delta; alpha; epsilon) since its first emergence in 2019.
Cucnhat P. Walker, Natalie P. Hurlock, Subrata Deb   +2 more
doaj   +1 more source